The reality of financial strain for breast cancer patients is not new news. A recent study suggests the financial toxicity associated with living with metastatic breast cancer may more than double over the next decade.
A study from the UNC Center for Health Promotion and Disease Prevention predicts that annual costs associated with metastatic breast cancer among United States women will be close to $152.4 billion in 2030. The large increase is due to a rise in the estimated cases of metastatic disease among younger women.
The study used the most recent U.S. census data as well as statistics from the National Cancer Institute to estimate how the number of women affected by metastatic breast cancer will change by 2030. Their model estimates a 54.8% increase in metastatic breast cancer diagnoses among women aged 18-64. This would translate to a rise in cases from 158,997 women living with the disease in 2015, to 246,194 in 2030. When combining this estimated data with the predicted annual cost of treatment, the future annual cost of metastatic breast cancer could reach $152.4 billion in 2030.
The study authors are hopeful that these statistics will promote more funding for early detection campaigns, access to care, and new treatments to help cure breast cancer.
Education and access to care are vital to early detection and prompt treatment. There are also many lifestyle factors that patients can consider to reduce their overall risk for developing breast cancer:
As always, it is always very important to follow up regularly with your healthcare team and schedule your annual breast cancer screening appointments as recommended.
There was very hopeful news this week for many patients with metastatic (stage 4) breast cancer.
The FDA has approved the use of the drug Tukysa (tucatinib) in combination with chemotherapy (trastuzumab and capecitabine) for the treatment of locally advanced HER2+ breast cancer that can’t be removed with surgery, or for stage 4 disease (including brain metastasis) in patients who have already received one or more prior treatments. In trial studies, 33% of patients treated with Tucatinib in combination with chemotherapy did not see their cancer progress in the first year and 2-year survival after starting treatment was 44.9%.
Based on the favorable results of a recent phase 2 study, the FDA also announced a fast-tracked approval of the drug Trodelvy (sacituzumab govitecan-hziy). The drug is specifically for patients with relapsed or refractory metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. According to the manufacturer, the drug specifically targets the receptor that encourages cancer growth and spread in the body. The study for Trodelvy included 108 patients. More that half of patients with stage 4 disease who responded to the drug maintained their response for six months or more. Some patients also experienced reduced tumor sizes. Encouragingly, 16.7% of patients maintained their positive response to the drug for a year or more.
As always, before beginning any new therapy, it is important to fully discuss all the potential benefits and side effects with your medical oncologist.